Table 2.
Risk of prostate cancer by quartiles and continuous measure of mtDNA copy number.
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | Continuous (log transformed) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| mtDNA copy number range | < 70 | 70 – 92 | 93 – 113 | > 113 | ||||||
| no. cases/no. controls | OR** | no. cases/no. controls | OR (95% CI) | no. cases/no. controls | OR (95% CI) | no. cases/no. controls | OR (95% CI) | OR (95% CI) | p-value | |
| All cases | 172/190 | 1.0 | 213/205 | 1.15 (0.87–1.53) | 180/189 | 1.06 (0.79–1.41) | 228/206 | 1.23 (0.93–1.62) | 1.23 (0.97–1.55) | 0.089 |
| Non-Aggressive | 150/190 | 1.0 | 171/205 | 1.06 (0.79–1.43) | 153/189 | 1.03 (0.76–1.40) | 201/206 | 1.25 (0.94–1.68) | 1.29 (1.01–1.65) | 0.044 |
| Aggressive | 24/190 | 1.0 | 42/205 | 1.84 (1.05–3.20) | 30/189 | 1.17 (0.64–2.13) | 28/206 | 1.13 (0.62–2.05) | 1.02 (0.64–1.63) | 0.933 |
| Stage | ||||||||||
| I/II | 157/190 | 1.0 | 183/205 | 1.08 (0.81–1.45) | 189/165 | 1.07 (0.79–1.44) | 211/206 | 1.25 (0.94–1.66) | 1.26 (0.99–1.61) | 0.057 |
| III/IV | 15/190 | 1.0 | 30/205 | 1.85 (0.96–3.55) | 15/189 | 0.94 (0.45–1.99) | 17/206 | 1.01 (0.49–2.09) | 0.92 (0.53–1.59) | 0.755 |
| Gleason Score | ||||||||||
| ≤ 6 | 97/190 | 1.0 | 134/205 | 1.25 (0.90–1.74) | 114/189 | 1.21 (0.86–1.70) | 151/206 | 1.45 (1.05–2.01) | 1.51 (1.15–1.98) | 0.003 |
| 7 | 58/190 | 1.0 | 51/205 | 0.83 (0.54–1.27) | 47/189 | 0.79 (0.51–1.22) | 59/206 | 0.93 (0.61–1.40) | 0.88 (0.62–1.26) | 0.483 |
| ≥ 8 | 14/190 | 1.0 | 27/205 | 1.91 (0.97–3.78) | 16/189 | 1.08 (0.51–2.28) | 16/206 | 1.06 (0.50–2.25) | 1.00 (0.56–1.79) | 0.998 |
All models are adjusted for age at diagnosis and year of blood draw. OR for all cases was estimated using logistic regression; ORs for subgroups estimated using polytomous regression.
Aggressive PCa defined as either Stage III or IV disease, or Gleason score ≥ 8 at diagnosis.
**
Reference category